Abstract Sacubitril/valsartan (LCZ696) is recommended for ejection fraction reduction in
heart failure. However, studies comparing the effects of sacubitril/valsartan in patients with …

A worsening renal function is prevalent among patients with cardiovascular disease,
especially heart failure (HF). Sacubitril/valsartan appears to prevent worsening of renal …

Patients with chronic kidney disease (CKD) are often complicated with heart failure with
preserved ejection fraction (HFpEF). However, several drugs, including angiotensin …

Real-life data confirming the favourable renal outcome in patients with heart failure (HF)
treated with Sacubitril/Valsartan, previously found in several trials (RCTs), are still scant. We …

Aims Sacubitril‐valsartan has been shown to have superior effects over angiotensin‐
converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure …

Background Sacubitril/valsartan, a new pharmacological class of angiotensin receptor
neprilysin inhibitor, is beneficial to heart failure through blocking the degradation of …

Background: Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients
with heart failure with reduced ejection fraction, but its effects on kidney function and cardiac …

Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …

Background Angiotensin receptor and neprilysin inhibition (ARNI) has been shown to
reduce cardiovascular mortality by 20% as compared with enalapril in a randomized …

Current guidelines recommend angiotensin receptor blocker neprilysin inhibitors
(ARNI)(sacubitril/valsartan) as a replacement for angiotensin-converting-enzymeinhibitor …